BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | May 1, 2020
Distillery Therapeutics

Disrupting hypoxia signaling to treat a muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy The PI3K-mTOR pathway inhibitors could treat facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle wasting disorder caused by inappropriate DUX4 expression, by disrupting the hypoxia signaling pathway. In a DUX4-expressing...
BC Extra | Apr 23, 2019
Company News

Fulcrum gets rights to GSK's shelved p38 kinase inhibitor

Following the failure of late-stage trials conducted by GSK in acute coronary syndrome and chronic obstructive pulmonary disease, Fulcrum will seek to revive the pharma's losmapimod for a rare genetic disease with an exclusive, worldwide...
BioCentury | Sep 5, 2018

Fulcrum’s genetic levers

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round. Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital,...
BC Innovations | Dec 22, 2016
Translation in Brief

Pin the tail

Stanford University researchers have provided preclinical proof of concept that adding polyadenine (polyA) tails to atypical sites on mRNAs could treat disease. Although the team applied the strategy to the transcript of the fibrosis target,...
BC Week In Review | Jun 1, 2015
Company News

Evotec, Facio deal

Facio and Evotec partnered to discover small molecules to treat facioscapulohumeral dystrophy (FSHD), a muscle wasting disease. The partners will develop a high throughput assay to screen for small molecules that increase activity of structural...
BC Innovations | Mar 14, 2013

GSK goes deep with DPAc

GlaxoSmithKline plc 's Discovery Partnerships with Academia program has struck new deals with laboratories at the Vanderbilt University School of Medicine and The Hospital for Sick Children to identify compounds for severe obesity and cystic...
BC Innovations | Jan 10, 2013

DUX4 partnership

Researchers at the Fred Hutchinson Cancer Research Center have identified a mutation that induces expression of the transcription factor double homeobox 4 and could be targeted in facioscapulohumeral muscular dystrophy. 1 Based on this and...
BC Week In Review | Dec 17, 2012
Company News

GlaxoSmithKline, Fred Hutchinson deal

GlaxoSmithKline and the research center partnered under GSK's Discovery Partnerships with Academia to develop products to treat facioscapulohumeral muscular dystrophy (FSHD). The center will receive an undisclosed upfront payment and research expenses and is eligible...
Items per page:
1 - 9 of 9